Elexacaftor / tezacaftor / ivacaftor vs Vanzacaftor / tezacaftor / deutivacaftor

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Cystic Fibrosis

Shared mechanism: CFTR · full Cystic Fibrosis pipeline

Elexacaftor / tezacaftor / ivacaftor · Trikafta

Marketed by Vertex Pharmaceuticals

Approved in Cystic Fibrosissmall molecule
Reliable signal

NCT03525444 · Phase 3 · completed

Trial 1 in the TRIKAFTA label was a 24-week, randomized, double-blind, placebo-controlled Phase 3 trial in 405 people aged 12 and older with one F508del variant and a minimal function variant. The single primary endpoint was the absolute change in percent predicted FEV1 at Week 4. TRIKAFTA improved it by 13.8 percentage points more than placebo (95% CI 12.1 to 15.4, P<0.0001), so the primary endpoint was met. Sources: the FDA label (TRIKAFTA) and the CT.gov posted results.

Next expected readout: April 2027 · NCT05331183 (registry estimate)

Reported efficacy

Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) (From Baseline at Week 4): Absolute change in ppFEV1 from baseline at Week 4 (interim analysis, 403 patients): treatment difference vs placebo 13.8 percentage points (95% CI 12.1 to 15.4), P<0.0001; CT.gov LS means +13.6 vs -0.2 (TRIKAFTA label section 14.1; CT.gov posted results). (met)

Result source: NCT03525444

Vanzacaftor / tezacaftor / deutivacaftor · Alyftrek

Marketed by Vertex Pharmaceuticals

Approved in Cystic Fibrosissmall molecule
Reliable signal

NCT05033080 · Phase 3 · completed

This was a randomized, quadruple-blind trial in 398 treated patients comparing the new combination against the active standard-of-care regimen. The primary endpoint, lung function (ppFEV1) at 24 weeks, met the pre-specified non-inferiority criterion (p<0.0001), with the new combination numerically matching or slightly exceeding the comparator (difference +0.2 percentage points, 95% CI -0.7 to 1.1).

Next expected readout: July 2029 · NCT05844449 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Cystic Fibrosis

There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.

Vanzacaftor / tezacaftor / deutivacaftor: registry results are on file for Cystic Fibrosis, but their comparison mappings are not yet available.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Elexacaftor / tezacaftor / ivacaftor
Absolute change in ppFEV1 from baseline at Week 4 (interim analysis, 403 patients): treatment difference vs placebo 13.8 percentage points (95% CI 12.1 to 15.4), P<0.0001; CT.gov LS means +13.6 vs -0.2 (TRIKAFTA label section 14.1; CT.gov posted results). NCT03525444 · Phase 3 · design grade: strong · publication or press release
Absolute change in ppFEV1 from baseline at Week 4 vs tezacaftor/ivacaftor: +10.4 vs +0.4; treatment difference 10.0 percentage points (95% CI 7.4 to 12.6), P<0.0001 (TRIKAFTA label section 14.1; CT.gov posted results). NCT03525548 · Phase 3 · design grade: strong · publication or press release

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Elexacaftor / tezacaftor / ivacaftor's landscape · Vanzacaftor / tezacaftor / deutivacaftor's landscape